CA
NZ
UK
AU
IND
US
Trend Structure: Textbook Sustained Uptrend — Seven-Week Bull Phase With No Structural Damage
Liquidia Corporation (NASDAQ: LQDA) delivered one of the most emphatic commercial readouts in the pulmonary hypertension space on Tuesday, sending its shares soaring 23.29 per cent to $52.15 as investors digested a first-quarter performance that left little room for equivocation. YUTREPIA, the company's inhaled …
Shares in Ensysce Biosciences (NASDAQ: ENSC) edged lower on Tuesday, falling 3.08 per cent to $0.3394, even as the company placed itself at the centre of one of the most consequential debates in contemporary pharmacology: how to engineer effective pain relief without handing patients …
Zai Lab Limited (NASDAQ: ZLAB) added 5.65 per cent on Tuesday to close at $19.65, lifted by news that the FDA has extended a second Fast Track Designation to zocilurtatug pelitecan — known within the oncology community as zoci — for the treatment of …
MoonLake Immunotherapeutics (NASDAQ: MLTX) advanced 9.38 per cent on Tuesday to $18.66, buoyed by confirmation that it has completed a productive final pre-BLA meeting with the US Food and Drug Administration for sonelokimab in hidradenitis suppurativa — a chronic, debilitating inflammatory skin condition that …
Exagen Inc. (NASDAQ: XGN) surged 25.42 per cent to $3.70 on Tuesday after the medical diagnostics company reported a first quarter that exceeded expectations on the metrics that matter most for a diagnosticsBusinessat this stage of its commercial development: volume, pricing, and the trajectory …
Zai Lab Limited (NASDAQ: ZLAB) added 5.65 per cent on Tuesday to close at $19.65, lifted by news that the FDA has extended a second Fast Track Designation to zocilurtatug pelitecan — known within the oncology community as zoci — for the treatment of …
Actuate Therapeutics (NASDAQ: ACTU) suffered a sharpReversalon Tuesday, declining 11.82 per cent to $2.91, in what may rank as one of the more counterintuitive market reactions of the day. The company had just announced that the US Food and Drug Administration had cleared its …
Galectin Therapeutics (NASDAQ: GALT) rose 6.67 per cent to $2.24 on Tuesday after the publication of its Phase 2b NAVIGATE trial results in Hepatology, one of the field's most respected peer-reviewed journals. The data — assessing belapectin in patients with metabolic dysfunction-associated steatohepatitis cirrhosis …
Moderna (NASDAQ: MRNA) gave back ground on Tuesday, declining 3.59 per cent to $52.40, even as the company found itself at the centre of an emerging outbreak narrative that has placed hantavirus — rarely a name that registers with mainstream investors — into the …
Please wait processing your request...